Celgene (CELG) Added to BofA/Merrill Lynch US 1 List

BofA/Merrill Lynch added Celgene (NASDAQ: CELG) to its US 1 List while maintaining a Buy rating and price target of $112.00.

Analyst Ying Huang notes CELG is one of the highest growth companies among the large-cap biotechs and they expect compounded annual revenues growth of 20% and EPS growth of 28% over the next three years. Shares are also trading at an attractive multiple of 20.5x forward estimates.

For an analyst ratings summary and ratings history on Celgene click here. For more ratings news on Celgene click here.

Shares of Celgene closed at $103.10 yesterday.

You May Also Be Interested In

• BofA Securities Starts Mobility Global (MBGL) at Neutral
• BofA says momentum style supported by earnings revisions
• BofA Adjusts US 1 List